-
公开(公告)号：US08629139B2
公开(公告)日：2014-01-14
申请号：US12574666
申请日：2009-10-06
IPC分类号： A61K31/536 , C07D498/14
CPC分类号： A61K45/06 , A61K31/536 , A61K31/5383 , A61K31/7036 , A61K33/06 , A61K47/02 , C07D498/14 , A61K2300/00
摘要： The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
摘要翻译： 本发明涉及用于治疗肺部炎症的方法和组合物。 特别地，提供了使用气溶胶左氧氟沙星或氧氟沙星来减少肺部炎症的方法和组合物。
-
2.发明申请Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease 审中-公开使用气溶胶抗生素治疗慢性阻塞性肺疾病公开(公告)号：US20120237564A1
公开(公告)日：2012-09-20
申请号：US13398310
申请日：2012-02-16
申请人： Michael N. Dudley , Neil Berkley , David C. Griffith , Jeffery S. Loutit , Elizabeth E. Morgan , Keith A. Bostian , Sanjay Sethi
发明人： Michael N. Dudley , Neil Berkley , David C. Griffith , Jeffery S. Loutit , Elizabeth E. Morgan , Keith A. Bostian , Sanjay Sethi
CPC分类号： A61K31/496 , A61K9/0078
摘要： The present invention relates to methods and compositions for treating obstructive pulmonary disorders. In particular, compositions and methods described herein relate to the use of an aerosolized antibiotic for treating obstructive pulmonary disorders including chronic obstructive pulmonary disorder (COPD) and chronic bronchitis (CB).
摘要翻译： 本发明涉及用于治疗阻塞性肺病的方法和组合物。 特别地，本文所述的组合物和方法涉及气雾化抗生素用于治疗阻塞性肺病，包括慢性阻塞性肺病（COPD）和慢性支气管炎（CB）的用途。
-
公开(公告)号：US07879795B2
公开(公告)日：2011-02-01
申请号：US11832626
申请日：2007-08-01
申请人： Tomasz Glinka , Keith Bostian , Olga Lomovskaya , Mark Surber , Dongxu Sun
发明人： Tomasz Glinka , Keith Bostian , Olga Lomovskaya , Mark Surber , Dongxu Sun
IPC分类号： A61K38/00
CPC分类号： A61K31/165 , A61K31/426 , A61K31/433 , A61K31/47 , A61K31/65
摘要： Disclosed herein are Efflux Pump Inhibitor (EPI) compounds that can be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. It is demonstrated that the EPIs can be used to increase the potency, decrease bacterial resistance and development of bacterial resistance, and increase killing effectivness of tigecycline. Also disclosed are methods of treatment and pharmaceutical compositions for co-administering tigecylcine with an EPI.
摘要翻译： 本文公开了可与抗微生物剂共同施用以治疗由耐药性病原体引起的感染的流出泵抑制剂（EPI）化合物。 EPI化合物是表现出组织积累倾向降低的软性药物。 证明EPI可用于增加效力，降低细菌耐药性和细菌耐药性的发展，并增加替加环素的杀伤效果。 还公开了治疗方法和药物组合物，用于与十二烷基苯共同施用EPI。
-
公开(公告)号：US20140066441A1
公开(公告)日：2014-03-06
申请号：US14012307
申请日：2013-08-28
发明人： Mark W. Surber , Keith A. Bostian , Michael N. Dudley , Olga Rodny (Lomovskaya) , David C. Griffith
IPC分类号： A61K9/00 , A61K31/5383
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
摘要翻译： 本文公开了适用于气雾化和使用这种制剂的氟喹诺酮类制剂用于气雾剂施用氟喹诺酮抗微生物剂以治疗肺细菌感染。 特别地，描述了专门配制并递送用于肺细菌感染的吸入性左氧氟沙星。 方法包括用于生产和使用所述组合物的吸入方案和制造方法。
-
公开(公告)号：US08524734B2
公开(公告)日：2013-09-03
申请号：US12604324
申请日：2009-10-22
IPC分类号： A61K31/00 , A61K31/44 , A61K31/4412 , A61K33/06 , A61K33/14 , A61K33/26 , A61K33/30 , A01N25/00 , A01N25/02 , A01N25/06 , A01N59/08
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
-
6.发明授权公开(公告)号：US07893020B2
公开(公告)日：2011-02-22
申请号：US11134147
申请日：2005-05-20
申请人： Tomasz Glinka , Keith Bostian , Mark Surber , Olga Lomovskaya , Dongxu Sun
发明人： Tomasz Glinka , Keith Bostian , Mark Surber , Olga Lomovskaya , Dongxu Sun
IPC分类号： A61K38/00
CPC分类号： C07K5/06086 , A61K38/00 , C07K5/0202 , C07K5/0215 , C07K5/06191 , C07K5/0819 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. The invention includes novel compounds useful as efflux pump inhibitors, compositions and devices comprising such efflux pump inhibitors, and therapeutic use of such compounds.
摘要翻译： 本发明涉及抗微生物剂领域，更具体地说，本发明涉及与用于治疗由耐药性病原体引起的感染的抗微生物剂共同施用的流出泵抑制剂（EPI）化合物。 EPI化合物是表现出组织积累倾向降低的软性药物。 本发明包括可用作外排泵抑制剂的新化合物，包含这种外排泵抑制剂的组合物和装置，以及这些化合物的治疗用途。
-
公开(公告)号：US07838532B2
公开(公告)日：2010-11-23
申请号：US11436875
申请日：2006-05-18
IPC分类号： A61K31/00 , A61K31/44 , A61K31/4412 , A61K33/00 , A61K33/06 , A61K33/14 , A61K33/26 , A61K33/30 , A01N25/00 , A01N25/02 , A01N25/06 , A01N59/08
CPC分类号： A61K9/0078 , A61K9/0075 , A61K9/08 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
摘要翻译： 本文公开了适用于气雾化和使用这种制剂的氟喹诺酮类制剂用于气雾剂施用氟喹诺酮抗微生物剂以治疗肺细菌感染。 特别地，描述了专门配制并递送用于肺细菌感染的吸入性左氧氟沙星。 方法包括用于生产和使用所述组合物的吸入方案和制造方法。
-
公开(公告)号：US08524735B2
公开(公告)日：2013-09-03
申请号：US12604347
申请日：2009-10-22
IPC分类号： A61K31/00 , A61K31/44 , A61K31/4412 , A61K33/00 , A61K33/06 , A61K33/14 , A61K33/26 , A61K33/30 , A01N25/00 , A01N25/02 , A01N25/06 , A01N59/08
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
摘要翻译： 本文公开了适用于气雾化和使用这种制剂的氟喹诺酮类制剂用于气雾剂施用氟喹诺酮抗微生物剂以治疗肺细菌感染。 特别地，描述了专门配制并递送用于肺细菌感染的吸入性左氧氟沙星。 方法包括用于生产和使用所述组合物的吸入方案和制造方法。
-
公开(公告)号：US20100166673A1
公开(公告)日：2010-07-01
申请号：US12604340
申请日：2009-10-22
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
-
公开(公告)号：US20100087416A1
公开(公告)日：2010-04-08
申请号：US12574680
申请日：2009-10-06
IPC分类号： A61K31/397 , A61K31/535 , A61P11/06 , A61P11/00
CPC分类号： A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
摘要翻译： 本发明涉及抗微生物剂领域。 特别地，本发明涉及用二价或三价阳离子配制的雾化氟喹诺酮类药物，并且具有改善的肺可用性，用于治疗和管理肺和上呼吸道的细菌感染。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.032 秒)
